Novo Nordisk
NVO
#27
Rank
S$460.83 B
Marketcap
$102.74
Share price
-2.45%
Change (1 day)
-40.85%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Novo Nordisk (NVO) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : S$60.11 Billion

According to Novo Nordisk's latest financial reports the company's total liabilities are S$60.11 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Novo Nordisk - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2024-12-31S$61.12 B50.31%
2023-12-31S$40.66 B33.53%
2022-12-31S$30.45 B19.57%
2021-12-31S$25.47 B42.76%
2020-12-31S$17.84 B29.78%
2019-12-31S$13.74 B11.47%
2018-12-31S$12.33 B8.88%
2017-12-31S$11.32 B5.76%
2016-12-31S$10.71 B15.26%
2015-12-31S$9.29 B17.11%
2014-12-31S$7.93 B21.82%
2013-12-31S$6.51 B19.98%
2012-12-31S$5.42 B-11.69%
2011-12-31S$6.14 B9.44%
2010-12-31S$5.61 B9.28%
2009-12-31S$5.14 B8.34%
2008-12-31S$4.74 B8.2%
2007-12-31S$4.38 B10.72%
2006-12-31S$3.96 B5.04%
2005-12-31S$3.77 B15.34%
2004-12-31S$3.26 B23.74%
2003-12-31S$2.64 B22%
2002-12-31S$2.16 B-8.3%
2001-12-31S$2.36 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
S$166.95 B 177.72%๐Ÿ‡บ๐Ÿ‡ธ USA
S$86.14 B 43.29%๐Ÿ‡บ๐Ÿ‡ธ USA
S$101.87 B 69.47%๐Ÿ‡บ๐Ÿ‡ธ USA
S$76.42 B 27.13%๐Ÿ‡ซ๐Ÿ‡ท France